A new therapeutic medicine based on the investigation of membrane transporter

• Project/Area Number: 24592390
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Okayama University
• Principal Investigator: EBARA Shin 岡山大学, 大学病院, 講師 (70379741)
• Co-Investigator(Kenkyū-buntansha): WATANABE Masami 岡山大学, 岡山大学病院, 准教授 (70444677)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 癌 / 抗癌剤耐性 / P-glycoprotein / 小胞体ストレス / REIC/Dkk遺伝子 / 膀胱癌 / アポトーシス誘導

Outline of Final Research Achievements

Recently, we found that over expression of secreted REIC/DKK-3 protein induced Endoplasmic reticulum stress in cancer cell and reduced the anticancer agent resistance. In this study, we analyzed the anticancer agent resistance in genitourinary cancer, associated with the mechanism of P-glycoprotein including ABC transporter superfamily, and validated the effects of REIC/DKK-3 gene therapy as new therapeutic medication of anticancer agent resistance.